Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
Disease-free survival significantly longer in patients with resected esophageal, gastroesophageal junction cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.